10099640Cell-Specific Targeting of Advanced Therapeutics via Next Generation Artificial Membrane-Binding ProteinsClosedCollaborative R&DInnovate UKThis project, inspired by the success of lipid nanoparticle (LNP) based COVID-19 vaccines that reached \>1B people worldwide, aims to harness Hone Bio's state-of-the-art Artificial Membrane-Binding Protein (AMBP) technology for the precise targeting of LNPs to specific cell populations. This innovative approach holds potential for delivering advanced cancer therapeutics, including CAR-T cells produced in the body, and vaccines against tumour and beyond. Success in this project will yield a new research platform to accelerate the development of targeted-LNP therapeutics, reduce off-target effects, which will be used internally but also deployed on the market to provide access to the powerful technology. It will enable targeting LNPs to be developed in a fraction of the time when compared to alternative chemistry-based approaches, and will enable high-throughput screening procedures. The project will also advance the AMBP technology in its preclinical development, accelerating its path to clinical readiness.